Episode

France’s biotech ecosystem: science, capital and scale

Podcast
BioSpace
Published
May 28, 2026
Duration seconds
1260
Processing state
not_requested
Canonical source
https://api.riverside.com/hosting-analytics/media/78432452d425c03a67089fed6cc1beb4049361ea17549188bdb0141243930ef5/eyJlcGlzb2RlSWQiOiJmMzI3NTAyZC0yZDA5LTRiNGQtYTM1Zi0xYTJhOWM0ODQxOWMiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmExNmI4YTk4M2Q0MGQ1NWRmYjg0MjczL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi01LTI3X18xMS0yNi0xLm1wMyJ9.mp3
Audio
https://api.riverside.com/hosting-analytics/media/78432452d425c03a67089fed6cc1beb4049361ea17549188bdb0141243930ef5/eyJlcGlzb2RlSWQiOiJmMzI3NTAyZC0yZDA5LTRiNGQtYTM1Zi0xYTJhOWM0ODQxOWMiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmExNmI4YTk4M2Q0MGQ1NWRmYjg0MjczL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi01LTI3X18xMS0yNi0xLm1wMyJ9.mp3
JSON
/v1/public/podcasts/biospace-6696251/episodes/france-s-biotech-ecosystem-science-capital-and-scale
Markdown
/podcast/biospace-6696251/france-s-biotech-ecosystem-science-capital-and-scale.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/france-s-biotech-ecosystem-science-capital-and-scale/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/biospace-6696251/france-s-biotech-ecosystem-science-capital-and-scale.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll be hearing from Ksenija Pavletic, partner and chief commercial officer at Jeito Capital and Thierry Laugel, managing partner at Kurma Partners. We dive into France’s biotech ecosystem and what still needs to happen for more early innovation to translate into investable, scalable biotech. Host ⁠Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Ksenija Pavletic , Partner and Chief Commercial Officer, Jeito Capital Thierry Laugel , Managing Partner, Kurma Partners Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.